Results 141 to 150 of about 8,948 (223)

Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning. [PDF]

Nat Commun, 2022
Falet JR, Durso-Finley J, Nichyporuk B, Schroeter J, Bovis F, Sormani MP, Precup D, Arbel T, Arnold DL.   +8 more
europepmc   +1 more source

Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials. [PDF]

Ther Adv Neurol Disord
Derfuss T, Bermel R, Lin CJ, Hauser SL, Kappos L, Vollmer T, Comi G, Giovannoni G, Hartung HP, Weber MS, Wang J, Jessop N, Chognot C, Craveiro L, Bar-Or A.   +14 more
europepmc   +1 more source

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. [PDF]

Pharmacoecon Open, 2023
Martins P, Vandewalle B, Félix J, Capela CM, Cerqueira JJ, Salgado AV, Ferreira DG, Monteiro I.   +7 more
europepmc   +1 more source

Optimizing premedications for multiple sclerosis patients treated with ocrelizumab: A randomized controlled trial. [PDF]

Mult Scler J Exp Transl Clin
Abbasi Kasbi N, Rezaei A, Montazeri R, Nikkhah Bahrami S, Rezaeimanesh N, Arab Bafrani M, Ghane Ezabadi S, Kohandel K, Khodaie F, Jahani S, Naser Moghadasi A, Azimi Saeen A, Navardi S, Heidari H, Ebadi Z, Sahraian MA.   +15 more
europepmc   +1 more source

Machine learning-based prediction of disease progression in primary progressive multiple sclerosis. [PDF]

Brain Commun
Gurevich M, Zilkha-Falb R, Sherman J, Usdin M, Raposo C, Craveiro L, Sonis P, Magalashvili D, Menascu S, Dolev M, Achiron A.   +10 more
europepmc   +1 more source

Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis. [PDF]

Mult Scler Relat Disord
Abdelhak A, Antweiler K, Kowarik MC, Senel M, Havla J, Zettl UK, Kleiter I, Hoshi MM, Skripuletz T, Haarmann A, Stahmann A, Huss A, Gingele S, Krumbholz M, Selge C, Friede T, Ludolph AC, Overell J, Koendgen H, Clinch S, Wang Q, Ziemann U, Hauser SL, Kümpfel T, Green AJ, Tumani H.   +25 more
europepmc   +1 more source

Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies. [PDF]

Neurotherapeutics
Albelo-Martínez M, Rizvi S.
europepmc   +1 more source

A data-driven model of disability progression in progressive multiple sclerosis. [PDF]

Brain Commun
Garbarino S, Tur C, Lorenzi M, Pardini M, Piana M, Uccelli A, Arnold DL, Cree BAC, Sormani MP, Bovis F.   +9 more
europepmc   +1 more source

Assessing Peripheral Blood Biomarkers and Predictive Patterns in Multiple Sclerosis Using Cytokines and Immune Gene Expression Profiles in Ocrelizumab-Treated Patients: Tracking Tumor Necrosis Factor. [PDF]

Int J Mol Sci
Jevtić B, Momcilovic N, Stegnjaić G, Lazarević M, Stanisavljević S, Tamas O, Veselinovic N, Budimkic M, Mesaros S, Miljković Đ, Pekmezovic T, Drulovic J, Nikolovski N.   +12 more
europepmc   +1 more source

Diagnostic overshadowing in primary progressive multiple sclerosis with coexisting tethered cord syndrome and long-standing urological dysfunction: a case report and literature review. [PDF]

BMC Neurol
Alsalloum T, Alsamman H, Alkerdi R, Alassad G.   +3 more
europepmc   +1 more source